BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1070 related articles for article (PubMed ID: 18695050)

  • 21. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.
    Bourgeat P; Chételat G; Villemagne VL; Fripp J; Raniga P; Pike K; Acosta O; Szoeke C; Ourselin S; Ames D; Ellis KA; Martins RN; Masters CL; Rowe CC; Salvado O;
    Neurology; 2010 Jan; 74(2):121-7. PubMed ID: 20065247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
    Wang Y; Klunk WE; Debnath ML; Huang GF; Holt DP; Shao L; Mathis CA
    J Mol Neurosci; 2004; 24(1):55-62. PubMed ID: 15314250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Accuracy of Amyloid versus
    Lesman-Segev OH; La Joie R; Iaccarino L; Lobach I; Rosen HJ; Seo SW; Janabi M; Baker SL; Edwards L; Pham J; Olichney J; Boxer A; Huang E; Gorno-Tempini M; DeCarli C; Hepker M; Hwang JL; Miller BL; Spina S; Grinberg LT; Seeley WW; Jagust WJ; Rabinovici GD
    Ann Neurol; 2021 Feb; 89(2):389-401. PubMed ID: 33219525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of brain amyloid β deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B.
    Kawai N; Kawanishi M; Kudomi N; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
    Brain Inj; 2013; 27(9):1026-31. PubMed ID: 23662609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
    Gomperts SN; Locascio JJ; Makaretz SJ; Schultz A; Caso C; Vasdev N; Sperling R; Growdon JH; Dickerson BC; Johnson K
    JAMA Neurol; 2016 Nov; 73(11):1334-1341. PubMed ID: 27654968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pittsburgh Compound-B (PiB) binds amyloid β-protein protofibrils.
    Yamin G; Teplow DB
    J Neurochem; 2017 Jan; 140(2):210-215. PubMed ID: 27943341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Amyloid-plaque imaging of the brain using PET].
    Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
    Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex.
    Sepulcre J; Grothe MJ; Sabuncu M; Chhatwal J; Schultz AP; Hanseeuw B; El Fakhri G; Sperling R; Johnson KA
    JAMA Neurol; 2017 Jul; 74(7):813-820. PubMed ID: 28558094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.
    Ng SY; Villemagne VL; Masters CL; Rowe CC
    Arch Neurol; 2007 Aug; 64(8):1140-4. PubMed ID: 17698704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of
    La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
    Chen CD; Joseph-Mathurin N; Sinha N; Zhou A; Li Y; Friedrichsen K; McCullough A; Franklin EE; Hornbeck R; Gordon B; Sharma V; Cruchaga C; Goate A; Karch C; McDade E; Xiong C; Bateman RJ; Ghetti B; Ringman JM; Chhatwal J; Masters CL; McLean C; Lashley T; Su Y; Koeppe R; Jack C; Klunk WE; Morris JC; Perrin RJ; Cairns NJ; Benzinger TLS
    Acta Neuropathol; 2021 Oct; 142(4):689-706. PubMed ID: 34319442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.